- Conditions
- Sporadic Inclusion Body Myositis (sIBM)
- Interventions
- BYM338 (Bimagrumab)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
- Interventions
- Pozelimab/Cemdisiran
- Combination Product
- Lead sponsor
- Austin Neuromuscular Center
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Sporadic Inclusion Body Myositis
- Interventions
- BYM338/bimagrumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 36 Years to 85 Years
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Orange, California • Sacramento, California + 8 more